416. Poor clinical outcomes of COVID-19 patients receiving rituximab during the Omicron era

BACKGROUND: Rituximab (RTX), a widely used anti-CD20 monoclonal antibody, has been suggested as a risk factor for poor outcomes of coronavirus disease 2019 (COVID-19). However, it remains largely unknown whether COVID-19 outcomes remain worse in patients receiving RTX compared to those not being tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chan Mi, Kang, Chang Kyung, Jo, Hyeon Jae, Choe, Pyoeng Gyun, Kim, Nam Joong, Park, Wan Beom, Oh, Myoung-don
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678911/
http://dx.doi.org/10.1093/ofid/ofad500.486

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678911/
http://dx.doi.org/10.1093/ofid/ofad500.486

Ejemplares similares